Nevada s horrifying death penalty plan to use an untested drug cocktail of fentanyl and ketamine slate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from slate.com Daily Mail and Mail on Sunday newspapers.
Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg
Important new option for reversing opioid overdoses
News provided by
Share this article
Share this article
LONDON, April 30, 2021 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the approval of KLOXXADO
TM (naloxone hydrochloride) nasal spray 8mg, by the US Food and Drug Administration (FDA) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
KLOXXADO
TM contains twice as much naloxone per spray as Narcan
® Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic.
Delays making deal affected guidance at last results briefing.
An increasing awareness of the dangers of opioid pain relief in the US healthcare system has provided an opening for NZX-listed drug maker AFT Pharmaceuticals, which today announced it has
Choose your best value subscription option here.
Already have an account? Login
Stock Takes: Trustpower receives bids, Synlait s new brand, AFT s US deal
27 Apr, 2021 10:14 PM
3 minutes to read
Trustpower has received indicative bids for its retail business. Photo / Bay of Plenty Times
NZ Herald
Trustpower, New Zealand s fifth biggest electricity company, said it had received a number of non-binding indicative bids for its retail business following its announcement of a strategic review in January. The board had reviewed the proposals and had progressed into the due diligence stage of the process, Trustpower said.
Read More
Tauranga-based Trustpower has more than 230,000 customers across electricity, gas and broadband.
The review was designed to test interest in the business while also exploring the merits and business case to establish a standalone generation business.
Delays making deal affected guidance at last results briefing.
An increasing awareness of the dangers of opioid pain relief in the US healthcare system has provided an opening for NZX-listed drug maker AFT Pharmaceuticals, which today announced it has signed an almost US$19 million deal to supply its main product Maxigesic for use in hospital IV systems in the US.
The deal is with Hikma Pharmaceuticals USA, whose parent company is listed on the London Stock Exchange. Once paperwork is filed next month in the US, a 12 to 15-month approval process will commence, with sales of the product into the US starting in about 18 months, all going